Carrick Therapeutics, a Dublin-headquartered biopharma firm, has landed a $35 million investment from Pfizer as it also confirmed the final closure of a $25 million Series C funding round.
The company which is developing pioneering treatments to defeat some of the most aggressive cancers was founded by Elaine Sullivan, a former vice-president for research and development at both Eli Lilly and AstraZeneca, in 2016.
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite: